PDCD1 and melanoma: Therefore, as PD-1 and CTLA4 have different mechanisms of action to regulate T-cell activation, combined treatment with PD-1- and CTLA4-inhibitors has demonstrated enhanced effectiveness in several clinical trials for advanced-stage melanoma [22,23].